Mesa Laboratories, Inc. - 10-Q Summary
Business Context and Reporting Period
Mesa Laboratories, Inc. is a smaller reporting company that manufactures and distributes electronic measurement systems and disposables for niche applications including renal treatment, food processing, and medical sterilization. This report covers the quarterly period ended December 31, 2010, and the nine-month period ended on the same date. The company operates two primary segments: Biological Indicators and Instrumentation Products.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2010 | Nine Months Ended Dec 31, 2010 |
|---|---|---|
| Net Sales | $7,652,000 | $22,861,000 |
| Gross Profit | $4,440,000 | $13,373,000 |
| Gross Margin | 58.0% | 58.5% |
| Net Income | $1,258,000 | $4,006,000 |
| Diluted EPS | $0.37 | $1.21 |
| Operating Cash Flow (9mo) | $7,031,000 | |
| Cash & Equivalents (End of Period) | $2,129,000 | |
| Total Debt (Current + Long Term) | $6,500,000 | |
| Current Ratio | 1.67:1 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 43.9% for the quarter and 45.6% for the nine-month period compared to the prior year. This growth was driven primarily by the acquisition of SGM Biotech, Inc. (April 2010) and the Torqo product line (December 2009).
- Profitability: Net income rose 9% for the quarter and 17% for the nine-month period. However, net profit margins declined from 22% to 18% year-to-date due to increased amortization expenses and a shift in product mix toward lower-margin Biological Indicator products.
- Balance Sheet: Total assets increased from $33.6 million to $47.6 million, largely due to acquisitions. Cash and cash equivalents decreased significantly from $10.5 million to $2.1 million, reflecting heavy capital deployment for acquisitions and facility purchases.
- Debt: The company incurred significant debt to finance acquisitions, including a $4.0 million revolving line of credit (fully utilized) and a $3.0 million reducing line of credit ($2.5 million remaining).
Guidance, Outlook, and Risks
- Acquisitions: The company completed the purchase of SGM Biotech, Inc. and the biological indicator product line of Apex Laboratories, Inc. in December 2010. Management expects the Apex acquisition to be accretive to earnings in the first full quarter of operations.
- Operational Changes: Production of Torqo products was moved in-house to the Lakewood, CO facility in December 2010. Management expects this to significantly improve margins for this product line in the remainder of fiscal 2011.
- Amortization: Due to recent acquisitions, amortization expense is expected to rise significantly in fiscal 2011 and subsequent years.
- Liquidity: While the company maintains a history of surplus cash flow, current cash reserves are lower due to acquisition funding. The company is minimizing stock buybacks to preserve liquidity for debt retirement and dividends.
- Risks: Risks include general economic conditions, competition in data logging and biological indicator markets, and the integration of acquired companies. The filing notes no material changes to risk factors from the previous 10-K.
Investor Verification Checklist
- Acquisition Integration: Verify the actual contribution of the Apex Laboratories and SGM Biotech acquisitions to Q4 and full-year 2011 revenue and margins.
- Debt Servicing: Monitor the company's ability to service $6.5 million in debt, particularly the $4.0 million revolving line which is fully utilized.
- Torqo Margins: Confirm that the in-house production of Torqo products achieves the projected cost reductions and margin improvements.
- Amortization Impact: Track the impact of increased intangible asset amortization on future operating income.
- Cash Position: Observe the trend in cash and cash equivalents, which dropped by over $8 million in the nine-month period.